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prostate cancer reveals microsatellite
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Background: There are multiple existing and emerging therapeutic avenues for metastatic prostate cancer, with a
common denominator, which is the need for predictive biomarkers. Circulating tumor DNA (ctDNA) has the potential
to cost-efficiently accelerate precision medicine trials to improve clinical efficacy and diminish costs and toxicity.
However, comprehensive ctDNA profiling in metastatic prostate cancer to date has been limited.
Methods: A combination of targeted and low-pass whole genome sequencing was performed on plasma cell-free
DNA and matched white blood cell germline DNA in 364 blood samples from 217 metastatic prostate cancer patients.
Results: ctDNA was detected in 85.9% of baseline samples, correlated to line of therapy and was mirrored by
circulating tumor cell enumeration of synchronous blood samples. Comprehensive profiling of the androgen
receptor (AR) revealed a continuous increase in the fraction of patients with intra-AR structural variation, from 15.
4% during first-line metastatic castration-resistant prostate cancer therapy to 45.2% in fourth line, indicating a
continuous evolution of AR during the course of the disease. Patients displayed frequent alterations in DNA repair
deficiency genes (18.0%). Additionally, the microsatellite instability phenotype was identified in 3.81% of eligible
samples (≥ 0.1 ctDNA fraction). Sequencing of non-repetitive intronic and exonic regions of PTEN, RB1, and TP53
detected biallelic inactivation in 47.5%, 20.3%, and 44.1% of samples with ≥ 0.2 ctDNA fraction, respectively. Only
one patient carried a clonal high-impact variant without a detectable second hit. Intronic high-impact structural
variation was twice as common as exonic mutations in PTEN and RB1. Finally, 14.6% of patients presented false
positive variants due to clonal hematopoiesis, commonly ignored in commercially available assays.
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Conclusions: ctDNA profiles appear to mirror the genomic landscape of metastatic prostate cancer tissue and
may cost-efficiently provide somatic information in clinical trials designed to identify predictive biomarkers.
However, intronic sequencing of the interrogated tumor suppressors challenges the ubiquitous focus on coding
regions and is vital, together with profiling of synchronous white blood cells, to minimize erroneous assignments
which in turn may confound results and impede true associations in clinical trials.
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Clonal hematopoiesisBackground
Prostate cancer is the most commonly detected male cancer
in Europe and the third major cause of cancer-related death
among men [1]. Although the majority of metastatic
hormone-naïve prostate cancers (mHNPCs) demonstrate a
reliable response to initial androgen deprivation therapy
which targets AR signaling, progression to a
castration-resistant state is inevitable. However, the treat-
ment landscape for metastatic castration-resistant prostate
cancer (mCRPC) is evolving with the recent approval of
several new drugs translating to an increased overall sur-
vival [2–6]. Multiple additional avenues exist as genomic
profiling of metastatic tissue revealed that the majority of
mCRPC patients harbor clinically relevant alterations be-
yond the AR signaling pathway [7].
The most promising non-approved treatment avenue
in metastatic prostate cancers (mPCs) exploits synthetic
lethality in treating homologous recombination-deficient
cancers with poly (ADP-ribose) polymerase (PARP)
inhibitors [8]. Approximately one fifth of mCRPC carry
mutations in DNA repair genes [7]. However, the muta-
tional signatures of biallelic inactivation are heteroge-
neous between different DNA repair genes [9], and
future studies are therefore needed to determine which
genes are associated with a response to PARP inhibition.
Approximately 3% of mPC are driven by microsatellite
instability (MSI) [7, 10]. Pembrolizumab recently became
the first drug to be approved by the U.S. Food and Drug
Administration based on the MSI phenotype, irrespect-
ive of tumor type [11]. Although checkpoint blockade
did not confer a survival advantage as compared with
placebo for chemotherapy-relapsed mCRPC [12], anec-
dotal cases have been reported to display partial or
complete responses [10, 13–15].
The emergence of additional drugs, both towards com-
mon and rare mPC phenotypes such as PTEN-deficient
[16, 17] and neuroendocrine cancers [18], raises ques-
tions of how to efficiently translate the multitude of
treatment options to improved patient outcomes. The
genomic heterogeneity of mCRPC [7] and, in turn, the
low response rates of currently approved drugs [2–5, 19,
20] argue for the urgent need of predictive biomarkers.
Ineffective trial-and-error decisions inevitably lead tounnecessary side effects and unsustainable costs [21].
The AR splice variant 7 (AR-V7) [22] demonstrated
promising results as a negative response biomarker for
androgen receptor signaling inhibitors. However,
follow-up studies have been unable to validate the initial
clear-cut finding [23, 24], and although AR-V7 is clearly
prognostic, clinical implementation remains debated due
to (1) lack of treatment options for AR-V7-positive
patients and (2) lack of data from a prospective clinical
trial demonstrating the predictive power of AR-V7 for
treatment selection [25]. Recently, Scher and colleagues
demonstrated increased survival for AR-V7-positive pa-
tients receiving taxanes in a blinded retrospective multi-
center study [26]. However, AR-V7 assay positivity and
taxane therapy were both correlated to tumor burden,
obscuring interpretation and further highlighting the
need for a prospective randomized clinical trial to deter-
mine if AR-V7 can be applied as a predictive biomarker
[27].
The lack of predictive biomarkers is in part due to the
difficulty of obtaining temporally matched metastatic tis-
sue as the majority of mPCs metastasize to the bone.
Multiple studies on the acquisition of tumor tissue with
or without direct image guidance report a range of suc-
cess rates [28–31]. A recent effort, focusing on meth-
odological improvements, obtained > 20% cell content in
the majority of bone biopsies [32]. Circulating tumor
DNA is a viable alternative to metastatic tissue with
demonstrated high fractions of ctDNA [33–36] enabling
sensitive detection of somatic variation, and direct com-
parisons to metastatic tissue have revealed high concord-
ance [33, 37, 38]. Circulating tumor DNA has several
advantages as sampling through simple blood draws is
fast, cost efficient, and without side effects and allows
for longitudinal monitoring and the detection of mul-
tiple resistance alleles during therapy [38, 39].
Although ctDNA has the potential to accelerate
biomarker-driven trials in mPC, several questions
remain unanswered, e.g. if it is possible to detect MSI
directly from liquid biopsies and how ctDNA fractions
correlate to line of therapy. The ctDNA fraction deter-
mines the sensitivity to detect somatic variation which
in turn has consequences for the design of prospective
Table 1 Clinical characteristics describing the study participants
Number Percentage
Patients 211* 100
Age at first sampling year, mean ± SD 73.0 ± 8.91
Tumor stage at diagnosis
T1/2 44 20.9
T3/4 50 23.7
M1 74 35.1
Node-positive 15 7.1
Not specified 28 13.3
Gleason score at diagnosis
≤ 7 72 34.1
8–10 108 51.2
Not specified 31 14.7
Primary treatment
ADT (± RT/CT) 125 59.2
Radical Px (± RT) 61 28.9
Radical Px + ADT 7 3.3
Other 18 8.5
Metastatic burden at first sampling
LN only 31 14.7
Bone only 73 34.6
Bone and LN 61 28.9
Visceral and bone and/or LN 34 16.1
Not specified 12 5.7
Stage at first sampling (all patients, n = 217)
mHNPC 23 10.6
mHSPC1 6 2.8
mCRPC 188 86.6
*Six individuals declined access to medical records
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present a retrospective analysis of 217 cases and 364
blood samples covering the entire spectrum of mPC.
The purpose of this study was to gather information
relevant for future liquid biopsy-driven biomarker stud-
ies with a focus on (1) how ctDNA fractions vary from
mHNPC to end stage castration-resistant disease; (2) a
rationale for how to treat samples with low ctDNA frac-
tion; (3) the relative impact of different types of somatic
variation, affecting the sequencing strategy; (4) the
detection of potentially predictive biomarkers; (5) and fi-
nally, how clonal expansions in the hematopoietic stem
cells [40–43] impact liquid biopsy profiling.
Methods
A detailed description of the methods is provided in Add-
itional file 1: Supplemental methods. In brief, mPC patients
were recruited in an all-comer cohort (n = 217), ranging
from hormone-naïve to castration-resistant, between 2014
and 2017 with histologically confirmed prostate adenocar-
cinoma (Table 1). Blood samples (n = 364) were collected at
the start of a new line of therapy (defined as “baseline” sam-
ple) or during a particular systemic therapy (defined as “fol-
low-up” sample). The complete study cohort (n = 217)
encompassed patients recruited as part of the ProBio (Pros-
tate Biomarkers) study (n = 72, Stockholm, Sweden) and
abiraterone- or enzalutamide-treated patients (n = 145) re-
cruited to the CORE-ARV-CTC study (Antwerp, Belgium).
The original purpose of the CORE-ARV-CTC cohort was
to investigate if profiling androgen receptor splice variants
in circulating tumor cells (CTCs) may predict response to
enzalutamide and abiraterone treatment. The result of this
analysis together with somatic alterations in AR and TP53
is presented in a separate manuscript [24]. Additionally, an-
onymous healthy donor blood (n = 36) was collected
(Stockholm, Sweden). The study was conducted in accord-
ance with the Declaration of Helsinki, after approval was
acquired by ethical committees in Belgium (Antwerp Uni-
versity Hospital, registration number: B300201524217) and
Sweden (Karolinska University Hospital, registration num-
ber: 2016/101-32). All patients provided a written informed
consent document. Plasma was enriched from 2 × 10 ml
(ProBio patients) or 4–5 ml (CORE-ARV-CTC patients)
EDTA blood and stored at − 80 °C within the same working
day, allowing for high-quality ctDNA profiling [44]. Germ-
line DNA was extracted from leftover EDTA blood. In
addition, for 340 out of 364 ctDNA-analyzed blood sam-
ples, an additional blood sample was collected in a CellSave
tube and shipped to the GZA Sint-Augustinus (Antwerp,
Belgium) for CTC enumeration within 72 h on the
FDA-cleared CellSearch platform (Menarini Silicon Biosys-
tems, Italy), as previously described [45]. Upon isolation,
0.1–50 ng of cell-free DNA (cfDNA) and 50 ng of germline
DNA were used to create the sequencing libraries(ThruPLEX Plasma-seq kit, Rubicon Genomics, USA).
Cell-free DNA profiling was performed with a mix of low--
pass whole genome sequencing and hybridization-capture
targeted sequencing (SeqCap EZ system, Roche Nimblegen,
USA). Germline samples were only processed by the latter.
The capture designs and their targeted regions are de-
scribed in Additional file 2: Table S1.
Low-level processing of the sequencing data was per-
formed as previously described [36] and analyzed as
described in detail in Additional file 1: Supplemental
methods, which allowed for identification of pathogenic
germline variants, copy-number alterations (CNAs),
small mutations, and structural variation in unique
regions in the human genome commonly mutated in
prostate cancer (bioinformatic tools and settings are
summarized in Additional file 3: Table S2). The detec-
tion of somatic alterations, which was copy-number ad-
justed, allowed the estimation of tumor burden (ctDNA
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from the cancer cells). Where somatic CNA analysis
suggested a higher tumor burden, it was instead calcu-
lated from the CNA profile. Additionally, the incorpor-
ation of microsatellites in the comprehensive capture
design allowed the evaluation of microsatellite instability
(MSI). Finally, the analysis of patient-matched cfDNA
and germline DNA samples, compared to a merged file
of all healthy donor blood samples as a control, allowed
the interrogation of clonal hematopoiesis. Statistical ana-
lysis was performed in R (v3.3.2) [46].
Results
Liquid biopsy profiling of metastatic prostate cancer
Comprehensive cfDNA profiling was performed on 217
mPC patients (Table 1). Single nucleotide variants,
copy-number alterations (CNAs), and genomic structural
rearrangements were interrogated using a combination of
in-solution hybridization capture-based and low-pass whole
genome sequencing. An evolution of capture designs was
applied as the project progressed, from a pan-cancer to a
prostate-specific approach to cost-efficiently maximize the
information content (Additional file 2: Table S1). The com-
prehensive designs were aimed at progression samples with
high tumor burden whereas the smaller designs were tai-
lored for cost-efficient deep sequencing. However, to in-
crease the sensitivity to detect, e.g., intronic structural
variation in AR, the majority of samples were proc-
essed with both a comprehensive and a smaller design
(Additional file 4: Table S3). The data was subse-
quently merged before variant calling. The average
coverage, taking merging into account, was 814×
(interquartile range 251–965) for cfDNA and 445×
(interquartile range 371–533) for germline DNA. Data
from all samples is presented here, where the number
of relevant samples is described for each section
(Additional file 5: Table S4). In total, 364 plasma
samples from 217 mPC patients were profiled. Circu-
lating tumor cell enumeration using the CellSearch
platform was performed from synchronous blood
draws on 340 of the 364 plasma samples.
Circulating tumor DNA fraction correlation to line of
therapy
Circulating tumor DNA was detected in the majority of
baseline samples (85.9%, Additional file 6: Figure S1).
However, as the fraction of ctDNA in the cfDNA influ-
ences the sensitivity to detect somatic variation, we inves-
tigated if tumor burden correlated to line of therapy and
blood draw timing (Additional file 7: Table S5). Compar-
ing baseline ctDNA fractions at different lines of therapy,
a significant increase was present between first- and
second-line mCRPC and third- and fourth-line mCRPC
(Fig. 1). The ctDNA fractions were significantly lower,comparing baseline and follow-up samples for mHNPC
and first-line mCRPC (Additional file 6: Figure S2). The
differences were not statistically significant for later lines
of therapy. The CTC counts were correlated to the ctDNA
fraction estimate (rho = 0.7, p < 0.0001) (Additional file 6:
Figure S3) and mimicked the ctDNA pattern in relation to
line of therapy (Fig. 1, Additional file 6: Figure S2).
Detection of microsatellite instability from cell-free DNA
Microsatellites were targeted and sequenced to enable
MSI-phenotype detection directly from cfDNA (Add-
itional file 2: Table S1 and Additional file 5: Table S4).
Using an in-house cohort of colorectal cancer samples
(Additional file 6: Figure S4), in silico dilution with
germline DNA demonstrated 100% sensitivity and 99%
specificity to detect MSI at 10% tumor purity and 10%
unstable microsatellites with the mSINGS algorithm
[47]. Applying mSINGS on ≥ 10% ctDNA fraction sam-
ples identified four cases with MSI out of 105 investi-
gated (Fig. 2). The proportion of MSI-positive cases
detected from ctDNA is concordant with a previous
study based on whole-exome sequencing of metastatic
tissue samples (two-sided Fisher’s exact test: p = 0.721)
[7].
Intronic sequencing of key tumor suppressors and
biallelic inactivation
Prostate cancer is mainly driven by CNAs, commonly
generated through chained structural rearrangements.
Chained events cause the majority of TMPRSS2-ERG
gene fusions [48], also observed in our data (Fig. 3,
Additional file 6: Figure S5). To allow detection of
structural rearrangements, capture probes were
designed towards the non-repetitive intronic and ex-
onic regions of PTEN, RB1, and TP53 in the
prostate-specific comprehensive design (CP design,
Additional file 2: Table S1, Additional file 5: Table S4,
Additional file 8: Table S6, Additional file 6: Figure
S6). Structural rearrangements, mutations, and
copy-number alterations were investigated in 165
cfDNA samples from 135 study participants profiled
with the CP design that passed the internal quality
control for structural variant calling (Additional file 1:
Supplemental methods, Additional file 5: Table S4).
Seventy-one samples (71/165, 43.0%) from 59 men
(59/135, 43.7%) had a ctDNA fraction ≥ 0.2, where all
classes of somatic variation were detectable. Biallelic
inactivation, through clonal high-impact variation, oc-
curred in 47.5% (28/59), 20.3% (12/59), and 44.1%
(26/59) of patients in PTEN, RB1, and TP53, respect-
ively. After excluding the MSI samples (carrying
high-impact passenger mutations in multiple genes),
all samples with a clonal high-impact variant also har-
bored a second event with only one exception: two
AB
Fig. 1 Tumor burden at different lines of therapy. a Violin plot of the circulating tumor cell counts per 7.5 ml of blood using the CellSearch platform
partitioned according to line of therapy. The black horizontal lines within the violin plots denote the median of the density estimate. Blue points represent
the circulating tumor cell counts in individual blood samples. A one-sided Wilcoxon rank sum test was applied to investigate if the baseline samples of, for
example, mCRPC1 had lower tumor burden than mCRPC2. Y-axis: log10 transformed circulating tumor cell counts. X-axis: line of therapy. b as a but for
circulating tumor DNA fraction. Y-axis: circulating tumor DNA fraction. In total, 364 blood samples from 217 cases are displayed here; however, only 340/
364 had a successful circulating tumor cell count. The dashed lines at 0.02, 0.10, and 0.20 denote the cutoffs to reliably detect point mutations, loss of
heterozygosity, and homozygous deletions, respectively. Abbreviations: mHNPC[number], metastatic hormone naïve prostate cancer and line of therapy;
mHSPC[number], metastatic hormone-sensitive prostate cancer and line of therapy; mCRPC[number], metastatic castration-resistant prostate cancer and
line of therapy; _B, baseline, blood samples collected at start of a new systemic therapy; _F, follow-up, blood samples collected during a systemic therapy;
Nbr, number of cell-free DNA samples profiled in each category
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both revealed a 392-kb deletion encompassing exon
9–10 of TP53 without any observable second hit.
Clonal dynamics during treatment
Subclonal high-impact variation was detected in multiple
patients. Both samples of P-GZA006 revealed subclonal
TP53 mutation accompanied by subclonal deletion
(Fig. 3). Before the start of abiraterone therapy, sample
20160759 of patient P-GZA4777 carried two subclonal
TP53 mutations (hotspot and frameshift), a subclonal
translocation in PTEN, and a weak AR amplification
(Additional file 6: Figure S7A). At progression (sample
20160890), the hotspot TP53 variant, PTEN transloca-
tion and the AR amplification were undetectable. How-
ever, the TP53 frameshift increased in allele fraction and
a new structural deletion in TP53 was found, in line with
TP53 loss being associated with rapid progression [49].
P-KLIN003 also experienced change in clonal compos-
ition during abiraterone therapy (Additional file 6:
Figure S7B). At baseline, two TP53 mutations weredetected. After therapy, the two displayed different be-
havior, decreasing and increasing in allele fraction. The
progressing clone also presented with TP53 loss of het-
erozygosity and multiple structural variants in AR.
Patient P-00039325 had high ctDNA fraction despite
being on androgen deprivation therapy for 3 weeks. Fol-
lowing docetaxel treatment, P-00039325 progressed after
215 days with a translocation in BRCA2 and concomi-
tant loss of heterozygosity (Additional file 6: Figure
S7C). In addition, an AR amplification and intra-AR
structural variation were detected.
Continuous evolution of somatic variation in the
androgen receptor
Comprehensive profiling of AR, including intronic se-
quencing, was performed in 275 mCRPC plasma sam-
ples from 177 individuals (Fig. 4a, Additional file 5:
Table S4). In total, 45.8% (126/275) of the samples and
50.3% (89/177) of the patients harbored one or more
variants in AR (high-impact mutation, structural variant,
or amplification) in at least one cfDNA sample
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Fig. 2 Detection of microsatellite instability from cell-free DNA. Microsatellite unstable tumors were identified from 121 samples (105 unique
patients) with ≥ 0.1 circulating tumor DNA fraction by plotting the number of mutations (Y-axis, including intronic and synonymous variants)
versus the fraction of unstable microsatellite loci (X-axis). Indels and single nucleotide variants are kept separate for each sample, colored according to the
right legend. The dashed vertical line at 0.10 fraction unstable microsatellites denotes the cutoff to reliably detect microsatellite instability. Two separate
cell-free DNA samples were profiled for P-GZA003, and both demonstrated microsatellite instability. Note that although individual P-KLIN014, sample
20170058, demonstrated > 0.1 fraction unstable microsatellite loci, it was classified as microsatellite stable. The sample had a high circulating tumor DNA
fraction (0.80), lacked an increase in number of mutations and displayed high copy-number burden, indicative of a chromosomal instability phenotype
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ation was closely correlated to amplification, and only 3/
51 patients (P-GZA4045, P-GZA4120, P-U001) carried
intra-AR structural variation without an accompanying
amplification. Structural variation was detected in
another three patient samples without amplification
(P-AZSJ022, P-KLIN002, P-UZA002), but weak amplifi-
cations were found in other samples from the same indi-
viduals, taken at other occasions. The fraction of
patients with structural variation in AR correlated to line
of therapy, ranging from 15.4% during first-line mCRPC
therapy to 45.2% in the fourth line. Overall, the percent-
age of individuals with any alteration in AR increased
from 37.4% in the first line to 76.9% in the fourth line,
indicating a continuous evolution of AR during the
course of the disease (Fig. 4b).
Alterations in DNA repair deficiency genes
Genes associated with DNA repair deficiency and com-
monly mutated in prostate cancer were targeted for muta-
tions and deletions (Additional file 2: Table S1).
Sequencing of germline DNA revealed high-impact vari-
ants in 8.92% (ATM, BRCA1, BRCA2, and CHEK2),similar to recent reports [50–52]. However, only 2/213
(excluding four germline DNA samples that failed pro-
cessing) carried pathogenic BRCA2 mutations, signifi-
cantly less than Pritchard et al. [51] and Mandelker et al.
[52] (two-sided Fisher’s exact test: p = 0.00329, p =
0.00129, respectively; Additional file 9: Table S7). Both re-
ported multiple occurrences of Ashkenazi Jewish founder
mutations such as the BRCA2 p.Ser1982Argfs*22, not ob-
served in this report. Coverage was manually inspected
using the integrative genomics viewer [53] which excluded
technical causes. This suggests differences in the under-
lying population demographics. Excluding MSI-positive
cases, 18 (8.29%) individuals had somatic biallelic inactiva-
tion of a DNA repair gene, whereas 39 (18.0%) had one
detectable alteration (Fig. 5, Additional file 8: Table S6).
Note, however, that the intronic regions were not targeted
in the current version of these capture designs rendering
structural variation undetectable, except close to exons or
baits designed for CNA purposes.
Clonal hematopoiesis causes false positive findings
Aberrant blood cell populations [40–43] have the poten-
tial to confound ctDNA mutational profiles when
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Fig. 4 Androgen receptor alterations. Comprehensive profiling of AR was performed in 275 cell-free DNA samples from 177 mCRPC patients.
a The upper panel displays the circulating tumor DNA fraction. The dashed lines at 0.02, 0.10, and 0.20 denote the cutoffs to reliably detect
point mutations, loss of heterozygosity, and homozygous deletions, respectively. Bottom panel, heatmap of the mutational landscape
detected in the androgen receptor from circulating tumor DNA profiling. Type of alteration is coded according to the bottom legend. For
visualization purposes, only samples with an alteration are shown here (126 samples from 89 individuals). Up to two mutations or structural
variants (forward and backslashes) are displayed per sample. X-axis: cell-free DNA samples sorted according to the number of alterations
detected. Patients with multiple samples are colored in blue. The asterisk indicates samples with microsatellite instability. b The fraction of
patients with alterations in the androgen receptor is categorized by type of alteration and line of therapy. Only high-impact mutations, e.g.,
hotspot mutations, are shown here. Intra-AR structural variation is colored according to the legend in a. The rightmost bar plot represents the
fraction of patients with any alteration in the androgen receptor. Abbreviations: mCRPC[number], metastatic castration-resistant prostate
cancer and line of therapy; _B, baseline; Nbr, number of samples profiled
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Fig. 3 Exonic and intronic profiling of circulating tumor DNA. The non-repetitive sequence was captured for the entire gene body of TP53, PTEN,
and RB1 in 165 cell-free DNA samples from 135 men. The somatic variants found in the 152 cell-free DNA samples from 124 men with detectable
circulating tumor DNA are shown here. TMPRSS2-ERG gene fusions or structural rearrangements in TMPRSS2 or ERG are also shown. The upper
panel displays the circulating tumor DNA fraction. The dashed lines at 0.02, 0.10, and 0.20 denote the cutoffs to reliably detect point mutations,
loss of heterozygosity, and homozygous deletions, respectively. Bottom panel, heatmap of the somatic alterations detected from circulating
tumor DNA profiling. Type of alteration is coded according to the bottom legend. For visualization purposes, up to two mutations or structural
variants (forward and backslashes) are displayed per patient. Triangles and boxes represent single nucleotide variants and indels, respectively.
Subclonal mutations are defined as having an allele frequency < 1/4 of the circulating tumor DNA fraction. The same definition was applied to
structural variants after median allele frequency adjustment with respect to the mutations. Synonymous point mutations are not displayed here.
Variants of unknown significance are non-synonymous single nucleotide variants outside hotspots, not annotated as pathogenic in variant
databases. Structural variants of unknown significance are, for example, confined to a single intron, without affecting neighboring exons. X-axis:
cell-free DNA samples sorted according to the circulating tumor DNA fraction. Patients with multiple samples are colored in blue. The asterisk
indicates samples with microsatellite instability. Samples described in the main text are connected with lines
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Fig. 5 Alterations in genes associated with DNA repair deficiency. The upper panel displays the circulating tumor DNA fraction. The dashed lines
at 0.02, 0.10, and 0.20 denote the cutoffs to reliably detect point mutations, loss of heterozygosity, and homozygous deletions, respectively.
Bottom panel, heatmap of the mutational landscape detected from circulating tumor DNA profiling of 327 cell-free DNA samples from 217
individuals. For visualization purposes, only the 76 samples with a relevant alteration are shown here. Type of alteration is coded according to the
bottom legend. Up to two mutations or structural variants (forward and backslashes) are displayed per patient. Triangles and boxes represent
single nucleotide variants and indels, respectively. Subclonal mutations are defined as having an allele frequency <1/4 of the circulating tumor
DNA fraction. The same definition was applied to structural variants after median allele frequency adjustment with respect to the mutations. The
BRCA2 structural variant of patient P-00039325, sample 3167424, was classified as borderline subclonal although relevant in the progressing clone
after chemohormonal treatment (Additional file 6: Figure S7C). Synonymous point mutations are not displayed here. Variants of unknown significance
are non-synonymous single nucleotide variants outside hotspots, not annotated as pathogenic in variant databases. Structural variants of unknown
significance are for example confined to a single intron, without affecting neighboring exons. X-axis: cell-free DNA samples sorted according to the
number of alterations detected in each gene in alphabetical order. Patients with multiple samples are colored in blue. The asterisk indicates samples
with microsatellite instability
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assess the potential impact and prevalence of genetically
aberrant blood cell expansions in our cohort, we investi-
gated copy-number and mutational data for indications
of aberrations present in both cfDNA and white blood
cell (WBC) DNA. We observed, in separate patients,
four cases of large arm-level copy-number alteration
(chr 11, 13, and 20) in WBC with coverage ratio and sin-
gle nucleotide polymorphism allele ratio suggesting a
cellularity between 40 and 65% and a focal CCND1 amp-
lification with coverage ratio 1.57, and all were similarly
observed in the cfDNA. Putative hematopoietic somatic
point mutations were interrogated in WBC DNA using
pooled healthy donor DNA as control and excluding
variants exceeding 25% allele ratio and outside known
somatic hotspots as likely germline. Thirty-seven
protein-altering variants were observed in another 29
patients and could be validated in patient-matched
cfDNA, including hotspot mutations in AKT1, BRAF,
CTNNB1, DNMT3A, NRAS, SF3B1, and TP53 (Fig. 6).In summary, 40 false positive variants in 31 patients
(14.6%) would have been included in ctDNA mutational
profiles if matched WBC had not also been sequenced.
Discussion
Genomics-guided therapy selection is arguably the most
promising avenue to remedy trial-and-error treatment
decisions and the accelerating costs of drugs [21]. How-
ever, the utility of tumor profiling is currently limited in
mPC due to the lack of validated predictive biomarkers.
Liquid biopsies have the potential to act as a tissue sub-
stitute and cost-efficiently accelerate trials designed to
identify predictive biomarkers. Therefore, we set out to
comprehensively profile cfDNA samples in mPC,
encompassing mHNPC to mCRPC, to gain knowledge
relevant for applying ctDNA in a clinical trial context.
Although this study was not designed as a predictive or
prognostic biomarker study, our data represents a valu-
able resource for the mPC ctDNA field. We demonstrate
the capability of ctDNA-based analysis, but at the same
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AZSJ043
AZSJ043
GZA4173
GZA4173
AZSJ001
AZSJ001
AZSJ038
AZSJ038
ONK7
ONK7
KLIN010
KLIN010
KLIN012
G001
G001
BCL2L12 13/334 P/X
ATM 257/3056 E/X
RQCD1 117/299 L/X
CCT8 86/548 I/T
SF3B1 666/1304 K/N
SF3B1 742/1304 G/D
ATM 1017/3056 Q/*
TCEB3 633/798 W/L
GNAS 50/1037 E/K
CHEK2 449/586 R/H
CCT8 86/548 I/T
DNMT3A 882/912 R/C
MLH1 618/756 K/T
TP53 237/393 M/I
GNAS 844/1037 R/C
ATM 2035/3056 T/A
TP53 162/393 I/F
IDH1 132/414 R/C
TP53 220/393 Y/C
GNAS 308/1037 P/L
DNMT3A 882/912 R/H
SF3B1 626/1304 N/D
SF3B1 700/1304 K/E
RQCD1 117/299 L/X
PIK3CA 726/1068 E/*
BRAF 581/766 N/S
NRAS 13/189 G/D
PTPN11 503/593 G/E
SF3B1 666/1304 K/R
NRAS 13/189 G/D
DNMT3A 882/912 R/C
CTNNB1 45/781 S/P
AKT1 17/480 E/K
0.0 0.2 0.4
Allele frequency
Consequence
frameshift_variant
missense_variant
stop_gained
missense_variant&splice_region_variant
Source
WBC_DNA
CF_DNA
Fig. 6 Clonal hematopoiesis. Presence of clonal expansions in the white blood cell compartment was investigated by somatic mutation (single
nucleotide variants and indels) analysis. Somatic mutations, supporting existence of clonal hematopoiesis, were identified in germline DNA
extracted from white blood cells by using a pool of healthy donor DNA as reference and subsequently validated in cell-free DNA from the same
individual. For each mutation, the amino acid position and total number of amino acids are given. Patients with multiple mutations are labeled
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individual. The inset legend explains the type and the source of each variant
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limited to, performing analysis where the somatic alter-
ations may originate from multiple independent sources
and ctDNA fraction may be low. In addition, we ad-
dressed several unanswered research questions of which
the key findings are as follows: (1) ctDNA fractions in-
creased gradually from the first to fourth line of therapy.
Baseline samples had higher ctDNA fraction compared
to follow-up samples, but the difference became
non-significant after the second line of mCRPC therapy;
(2) in samples with high tumor burden, inactivation of
key tumor suppressors was biallelic rather than monoal-
lelic, with only one exception, providing a rationale for
assuming a second hit in low ctDNA fraction samples
with insufficient sensitivity to detect the second hit; (3)
clonal high-impact structural variation is twice as com-
mon as point mutations, which challenges the traditional
focus on coding regions; (4) the three potentially clinic-
ally valuable biomarkers in mPC, microsatellite instabil-
ity, mutations in genes associated with DNA repair
deficiency and AR aberrations were detected at expectedrates; (5) clonal hematopoiesis occurs frequently, de-
manding synchronous WBC profiling to avoid false posi-
tive variant calls.
Due to the genomic diversity of metastatic cancer, resist-
ance will always arise to single-agent therapies where the
duration of response is correlated to the number of cancer
cells in a patient [54]. Towards end-stage disease, progres-
sion will occur more rapidly, regardless of therapy, with the
exception of extreme responders to immunomodulators
[14]. Molecular biomarker-driven clinical trials are com-
monly targeting patients where no approved treatment
options remain, although primary outcomes may be hard
to achieve if disease burden is too high [55]. Consequently,
tumor burden as ctDNA fraction or CTC counts is strongly
correlated to conventional outcome measurements [49, 56].
Recently, simple cfDNA concentration estimates were dem-
onstrated to prognosticate patients in a retrospective ana-
lysis of two phase III clinical trials [57]. Here, cfDNA
concentration was strongly correlated to ctDNA fraction
(Additional file 6: Figure S8) suggesting that cfDNA con-
centration estimation is a surrogate for ctDNA fraction.
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fore has the greatest potential early in the course of the
disease. Paradoxically, we find that liquid biopsies carry
more information towards end-stage disease and cur-
rently harbor limited information in a significant fraction
of patients starting first- and second-line mCRPC ther-
apy due to low ctDNA fraction (Fig. 1). The tumor bur-
den increased with new systemic (baseline) treatments,
from the first to second line and third to fourth. We
could not detect a significant difference between second
and third baseline samples, likely reflecting the hetero-
geneity of the treatment sequencing and responses in
this all-comers cohort. Comparing the baseline samples,
the fraction where it was possible to identify homozy-
gous deletions increased steadily from one third (33/99,
before start of first systemic mCRPC treatment) to
approximately 50% (59/126, before start of second/third
systemic mCRPC treatments) and finally to more than
two thirds (11/15, before start of fourth systemic
mCRPC treatment). As a consequence, the fraction of
patients with BRCA2 homozygous deletion detected
here (1.38%, 3/217) was lower than previously reported
from two studies analyzing tumor tissue from metastatic
patients (2.67%, 4/150 and 4.54%, 5/110) [7, 58]. How-
ever, the difference was not statistically significant (two--
sided Fisher’s exact test: p = 0.450 and p = 0.124,
respectively).
A potential solution for the low ctDNA fraction sam-
ples may be a complementary approach using CTCs to
gain insight into ploidy and CNA and ctDNA for muta-
tions and structural rearrangements. However, there are
some limitations: we show that CTC counts correlate
with ctDNA fraction (Additional file 6: Figure S3), and
patients with low ctDNA fraction starting first- and
second-line mCRPC therapy, with few exceptions, have
low CTC counts (Additional file 6: Figure S9); previous
work demonstrates poor success rate (~ 10%) in obtain-
ing high-quality CTC sequencing data from isolated cells
[59, 60] necessitating multiple 10-ml blood tubes for
CTC analysis in first- and second-line patients. However,
recent improvements in harvesting metastatic tissue [32]
may provide a fallback if ctDNA profiling fails to identify
any relevant biomarkers. As the success rate of harvest-
ing high-quality metastatic tissue is also correlated to
tumor burden [29, 30], prospective validation is needed
to establish the most feasible approach.
The inherent challenges to complement ctDNA profil-
ing inspired us to investigate the necessity of observing a
second hit to infer tumor suppressor deficiency. By deep
sequencing of all non-repetitive intronic and exonic
regions in TP53, PTEN, and RB1 in high ctDNA fraction
samples, we investigated whether detection of one clonal
high-impact variant is adequate to infer biallelic inactiva-
tion. Out of 71 samples in 59 men with ≥ 0.2 ctDNAfraction, 47.5%, 20.3%, and 44.1% harbored biallelic in-
activation of PTEN, RB1, and TP53, respectively (Fig. 3).
Only one patient carried a clonal high-impact variant, a
deletion in TP53, without a detectable event on the
other allele. These data are encouraging as a large frac-
tion of TP53 was not possible to sequence due to repeti-
tive DNA (Additional file 6: Figure S6). The observation
is consistent with exome sequencing of 150 mCRPC tis-
sues which revealed that biallelic inactivation always had
occurred if a high-impact event was observed in a key
tumor suppressor such as PTEN or RB1 [7]. Interest-
ingly, residual breakpoints remained in 5/17 samples
with a homozygous deletion in PTEN, which is detect-
able, even when tumor burden is low.
The comprehensive profiling of AR surprisingly
revealed that 11 out of 85 amplified mCRPC cfDNA
samples harbored hotspot mutations in AR. However,
concomitant presence of amplification and mutations in
a low fraction of cases has previously been described
[34, 49]. Speculatively, the multiple existing therapies to-
wards the AR signaling pathway will exert selection
pressure differently. This will lead to a complex AR
phenotype, where for example an amplified AR is first
detectable after first-line androgen deprivation therapy.
Subsequent abiraterone treatment may give rise to spe-
cific point mutations causing the simultaneous presence
of both mutations and amplifications in AR. These spec-
ulations are supported by recently published data [49]
demonstrating that AR amplifications are not prognostic
in the context of abiraterone or enzalutamide treatment,
causing a selective pressure on other AR and non-AR
alterations as a consequence of therapy.
The advances in targeted sequencing of cancer have
rapidly been adopted by multiple companies and trans-
formed into commercially available ctDNA tests [61–
63]. Two of these platforms were recently compared
with surprisingly low concordance [64]. The lack of ac-
companying white blood cell germline profiling makes it
hard to separate germline variation from somatic [65]
and impossible to distinguish clonal hematopoiesis [40–
43] from ctDNA unless the ctDNA fraction is high with
distinct features of the disease, e.g., the TMPRSS2-ERG
gene fusion. In our study, 14.6% of patients harbored
clonal expansions in the WBC compartment. Their som-
atic alterations, detected in germline DNA, were vali-
dated in cfDNA from the same individual. However,
absolute confirmation of the cell of origin for clonal
hematopoiesis events would require investigations in-
volving fluorescence-activated cell sorting of the WBC
populations followed by Sanger sequencing or preferably
single-cell sequencing, which is beyond the scope of this
study. As the targeted sequencing applied here only cov-
ered 60 out of 327 driver mutations associated with
clonal expansions in the blood [41], the majority of men
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A recent report used digital droplet PCR to investigate
hotspot mutations in three genes, commonly mutated in
hematopoietic malignancies, in WBC DNA from pa-
tients previously profiled with a commercial cfDNA
assay [66]. A large fraction of the mutations was de-
tected in the WBC DNA, corroborating our conclusions
that to avoid false positive variant calls, sequencing of
WBC DNA should be undertaken to the same or higher
depth as the cell-free DNA. We therefore discourage the
use of commercial assays that only analyze cfDNA from
plasma.
Although multiple potentially predictive biomarkers
have been reported for metastatic prostate cancer, no
level 1 evidence currently exists from prospective ran-
domized clinical trials. Based on our experience to date,
we consider ctDNA profiling to be at Technology Readi-
ness Level 7 according to the definition applied in the
Horizon 2020 calls [67]. We have therefore initiated a
prospective outcome-adaptive, multi-arm, open-label,
multiple-assignment randomized biomarker-driven trial
in patients with mCRPC where ctDNA profiling will be
applied to identify somatic alterations (ProBio, EudraCT
Number 2018-002350-78). The goal of the trial is to de-
termine whether treatment choice based on a biomarker
signature can improve progression-free survival com-
pared to standard of care in patients with mCRPC and
to evaluate the predictive capability of the investigated
biomarker signatures.Conclusions
This study strengthens the accumulating evidence that
ctDNA profiling mirrors the somatic alteration landscape
from metastatic tissue by demonstrating, for the first time,
that the MSI phenotype may be detected directly from
cell-free DNA. To enable acceleration of clinical trials
through ctDNA analysis, intronic sequencing of tumor sup-
pressors in combination with synchronous profiling of white
blood cells must be applied to prevent inaccurate somatic
variant calls, which in turn may reduce the power to identify
predictive biomarkers.Additional files
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